272 related articles for article (PubMed ID: 25223736)
1. Molecular and cellular basis of bone resorption.
Gruber R
Wien Med Wochenschr; 2015 Feb; 165(3-4):48-53. PubMed ID: 25223736
[TBL] [Abstract][Full Text] [Related]
2. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
Sims NA; Ng KW
Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416
[TBL] [Abstract][Full Text] [Related]
3. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cathepsin K for treatment of osteoporosis.
Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
[TBL] [Abstract][Full Text] [Related]
5. Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.
Ren ZY; Machuca-Gayet I; Domenget C; Buchet R; Wu Y; Jurdic P; Mebarek S
PLoS One; 2015; 10(7):e0132513. PubMed ID: 26168340
[TBL] [Abstract][Full Text] [Related]
6. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
7. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
8. [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?].
Neumann E
Z Rheumatol; 2006 Sep; 65(5):400, 402-6. PubMed ID: 16924451
[TBL] [Abstract][Full Text] [Related]
9. Advances in osteoclast biology resulting from the study of osteopetrotic mutations.
Segovia-Silvestre T; Neutzsky-Wulff AV; Sorensen MG; Christiansen C; Bollerslev J; Karsdal MA; Henriksen K
Hum Genet; 2009 Jan; 124(6):561-77. PubMed ID: 18987890
[TBL] [Abstract][Full Text] [Related]
10. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
11. Secretion of PDGF isoforms during osteoclastogenesis and its modulation by anti-osteoclast drugs.
Rahman MM; Matsuoka K; Takeshita S; Ikeda K
Biochem Biophys Res Commun; 2015 Jun; 462(2):159-64. PubMed ID: 25951977
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of suppressing osteoclast formation versus function.
Teitelbaum SL
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii61-ii63. PubMed ID: 27856662
[TBL] [Abstract][Full Text] [Related]
14. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
15. Rankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model.
To TT; Witten PE; Renn J; Bhattacharya D; Huysseune A; Winkler C
Development; 2012 Jan; 139(1):141-50. PubMed ID: 22096076
[TBL] [Abstract][Full Text] [Related]
16. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
17. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
18. Osteoclast-osteoblast communication.
Matsuo K; Irie N
Arch Biochem Biophys; 2008 May; 473(2):201-9. PubMed ID: 18406338
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
